The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 21, 2025
Filed:
Oct. 02, 2020
Applicant:
Tae Life Sciences, Foot Hill Ranch, CA (US);
Inventors:
Sohye Kang, Torrance, CA (US);
Morrison Kendall, Santa Monica, CA (US);
Assignee:
TAE Life Sciences, LLC, Irvine, CA (US);
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01);
U.S. Cl.
CPC ...
C07K 16/28 (2013.01); A61K 47/68031 (2023.08); A61K 47/6851 (2017.08); A61P 35/00 (2018.01); C07K 16/2863 (2013.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/71 (2013.01);
Abstract
Antibodies that bind Her2, EGFR, Trop2, CDH3 or other TAAs containing a triple mutation at L234A, L235A, and L328C and methods of making such triple mutated antibodies are disclosed herein. Consequently, the triple mutated antibodies contain a modified effector function through Fc silencing and are capable of site-specific conjugation at L328C to form an antibody-drug-conjugate (ADC) which can be administered to patients and provide a method of treating cancer, immunological and neurological disorders.